Outlook Therapeutics (OTLK) Net Income towards Common Stockholders (2015 - 2026)
Outlook Therapeutics (OTLK) posted quarterly Net Income towards Common Stockholders of -$4.5 million for Q1 2026, up 90.39% year-over-year from -$2.3 million in Q1 2025, and up 80.69% quarter-over-quarter from -$23.1 million in Q4 2025.
Outlook Therapeutics (OTLK) Net Income towards Common Stockholders (2015 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has reported Net Income towards Common Stockholders for 12 consecutive years, with -$4.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders rose 90.39% year-over-year to -$4.5 million; the TTM figure through Mar 2026 stood at -$61.0 million (down 388.61% YoY), while the FY2025 annual figure was -$62.4 million, up 17.17% from the prior year.
- Net Income towards Common Stockholders grew to -$4.5 million in Q1 2026 per OTLK's latest filing, from -$23.1 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $44.4 million in Q2 2024 and bottomed at -$114.3 million in Q1 2024.
- Historically, Net Income towards Common Stockholders has averaged -$16.2 million across 5 years, with a median of -$14.3 million in 2022.
- On a YoY basis, Net Income towards Common Stockholders climbed as much as 314.8% in 2024 and fell as far as 1617.52% in 2024.
- Outlook Therapeutics' Net Income towards Common Stockholders stood at -$18.7 million in 2022, then surged by 40.1% to -$11.2 million in 2023, then surged by 255.46% to $17.4 million in 2024, then sank by 232.69% to -$23.1 million in 2025, then jumped by 80.69% to -$4.5 million in 2026.
- Business Quant data shows OTLK's Net Income towards Common Stockholders at -$4.5 million in Q1 2026, -$23.1 million in Q4 2025, and -$13.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Outlook Therapeutics | 88.50 Mn | 77.26 Mn | -8,265.00 | -20.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.45 Mn |
| Dec 31, 2025 | -23.06 Mn |
| Sep 30, 2025 | -13.29 Mn |
| Jun 30, 2025 | -20.15 Mn |
| Mar 31, 2025 | -46.36 Mn |
| Dec 31, 2024 | 17.38 Mn |
| Sep 30, 2024 | 5.69 Mn |
| Jun 30, 2024 | 44.41 Mn |
| Mar 31, 2024 | -114.29 Mn |
| Dec 31, 2023 | -11.18 Mn |
| Sep 30, 2023 | -12.99 Mn |
| Jun 30, 2023 | -20.68 Mn |
| Mar 31, 2023 | -6.65 Mn |
| Dec 31, 2022 | -18.66 Mn |
| Sep 30, 2022 | -14.35 Mn |
| Jun 30, 2022 | -17.54 Mn |
| Mar 31, 2022 | -19.70 Mn |
| Dec 31, 2021 | -14.46 Mn |
| Sep 30, 2021 | -13.40 Mn |
| Jun 30, 2021 | -12.20 Mn |